Alzamend Neuro, Inc.
ALZN
$2.22
-$0.14-5.93%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.93% | 3.33% | -21.42% | 15.70% | -34.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.57% | 33.97% | -61.00% | -53.20% | -72.70% |
| Operating Income | -180.57% | -33.97% | 61.00% | 53.20% | 72.70% |
| Income Before Tax | -177.37% | -33.81% | 60.96% | 53.15% | 72.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -177.37% | -33.81% | 60.96% | 53.15% | 72.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -177.37% | -33.81% | 60.96% | 53.15% | 72.38% |
| EBIT | -180.57% | -33.97% | 61.00% | 53.20% | 72.70% |
| EBITDA | -181.40% | -34.50% | 61.29% | 53.43% | 72.97% |
| EPS Basic | 88.76% | 78.16% | 95.01% | 90.95% | 76.39% |
| Normalized Basic EPS | 88.76% | 85.62% | 95.01% | 91.29% | 76.39% |
| EPS Diluted | 88.76% | 78.16% | 95.01% | 90.95% | 76.39% |
| Normalized Diluted EPS | 88.76% | 85.62% | 95.01% | 91.29% | 76.39% |
| Average Basic Shares Outstanding | 2,368.93% | 829.80% | 682.02% | 438.27% | 17.01% |
| Average Diluted Shares Outstanding | 2,368.93% | 829.80% | 682.02% | 438.27% | 17.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |